Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $6.15 USD
Change Today +0.24 / 4.06%
Volume 1.3M
INO On Other Exchanges
As of 8:10 PM 10/5/15 All times are local (Market data is delayed by at least 15 minutes).

inovio pharmaceuticals inc (INO) Snapshot

Previous Close
Day High
Day Low
52 Week High
10/20/14 - $13.04
52 Week Low
10/2/15 - $5.32
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

inovio pharmaceuticals inc (INO) Related Businessweek News

No Related Businessweek News Found

inovio pharmaceuticals inc (INO) Details

Inovio Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops active DNA immunotherapies and vaccines in combination with proprietary electroporation delivery devices to prevent and treat cancers and infectious diseases. The company’s SynCon immunotherapy design has the ability to break the immune system’s tolerance of cancerous cells; and SynCon product design is also intended to facilitate cross-strain protection against known, as well as new unmatched strains of pathogens, such as influenza. It has completed, current or planned clinical programs of its proprietary SynCon immunotherapies for HPV-caused pre-cancers and cancers, prostate cancer, breast/lung/pancreatic cancer, hepatitis C virus, hepatitis B virus, HIV, influenza, and Ebola. Inovio Pharmaceuticals, Inc. has collaborative development agreement with GeneOne Life Sciences to co-develop an Ebola vaccine through phase I clinical trials. Inovio Pharmaceuticals, Inc. was founded in 1979 and is headquartered in Plymouth Meeting, Pennsylvania.

106 Employees
Last Reported Date: 03/16/15
Founded in 1979

inovio pharmaceuticals inc (INO) Top Compensated Officers

Chief Executive Officer, President, Director ...
Total Annual Compensation: $964.7K
Chief Financial Officer
Total Annual Compensation: $475.4K
Chief Operating Officer
Total Annual Compensation: $486.8K
Chief Medical Officer
Total Annual Compensation: $491.1K
Compensation as of Fiscal Year 2014.

inovio pharmaceuticals inc (INO) Key Developments

Inovio Pharmaceuticals, Inc. Receives $24 Million Option Grant from Defense Advanced Research Projects Agency to Advance Ebola Program Development

Inovio Pharmaceuticals, Inc. announced that the U.S. Defense Advanced Research Projects Agency (DARPA) has exercised its option to provide an additional $24 million to support the Inovio-led development of multiple treatment and prevention approaches against Ebola. The option exercise, part of the $45 million Ebola program grant announced in April when Inovio received an initial $21 million award, was contingent upon Inovio successfully leading the completion of certain pre-clinical and clinical development milestones. DARPA has funded this program to develop a DNA-based vaccine against Ebola, a therapeutic DNA-based monoclonal antibody product (dMAb) to treat Ebola infection, and a conventional monoclonal antibody to treat Ebola. In the intervening period from the grant award in April, Inovio and its collaborators have accomplished: Full enrollment of 75 volunteers for the phase I clinical study for Inovio's Ebola vaccine, INO-4212. Complete protection of vaccinated monkeys from a lethal Ebola virus challenge. Significant pre-clinical proof-of-concept demonstrated in animal models for the potential of its dMAb technology including with Ebola dMAb constructs. Screening of different Ebola dMAbs in pre-clinical studies is ongoing. Inovio recently reported the publication of its anti-dengue dMAb demonstrating protection against lethal challenge.

Inovio Pharmaceuticals, Inc. Announces First Patient Dosed with Universal HIV Vaccine

Inovio Pharmaceuticals, Inc. announced that the first patient has been dosed in a phase I trial to evaluate safety and tolerability of PENNVAX-GP, Inovio's 'universal' DNA vaccine for HIV. This human study is in collaboration with the HIV Vaccine Trials Network (HVTN). The trial will measure immune responses following administration of the vaccine in four groups of healthy subjects receiving the vaccine with and without an immune activator (IL-12) and delivered into muscle or skin using Inovio's CELLECTRA delivery technology. This study is conducted by the HVTN and funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). Development of the PENNVAX-GP vaccine, which targets multiple clades of HIV—providing global coverage—has been funded through a $25 million NIAID contract awarded to Inovio and its collaborators. Earlier this year, Inovio and its collaborators were awarded a five-year $16 millionIntegrated Preclinical/Clinical AIDS Vaccine Development (IPCAVD) grant from NIAID. This new five-year program grant was awarded based on a peer-reviewed meritorious proposal by Dr. David Weiner, from the University of Pennsylvania and chair of Inovio's scientific advisory board, and Inovio.

Inovio Pharmaceuticals, Inc. Presents at Citi 10th Annual Biotech Conference, Sep-09-2015

Inovio Pharmaceuticals, Inc. Presents at Citi 10th Annual Biotech Conference, Sep-09-2015 . Venue: Mandarin Oriental New York, 80 Columbus Circle, New York, NY 10023, United States. Speakers: J. Joseph Kim, Chief Executive Officer, President, Director and Member of Finance Committee.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
INO:US $6.15 USD +0.24

INO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Advaxis Inc $11.23 USD +0.30
Genocea Biosciences Inc $6.67 USD -0.26
GenVec Inc $2.02 USD 0.00
Transgene SA €2.74 EUR -0.06
Vical Inc $0.46 USD +0.0108
View Industry Companies

Industry Analysis


Industry Average

Valuation INO Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 27.1x
Price/Book 2.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 18.4x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact INOVIO PHARMACEUTICALS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at